Dr. Diamandis’ research focuses on four areas including: proteomics, tumor markers, kallikrein biology and pathophysiology, with efforts on cancer and other diseases including neurodegeneration, inflammation and skin disorders. In terms of kallikrein biology, the laboratory has cloned numerous novel genes including those that belong to the kallikrein gene family which encode a group of related serine proteases. Dr. Diamandis is specifically interested in kallikrein gene structure and transcriptional regulation, protein function and enzymology, discovery of physiological pathways involving kallikreins, identification of physiological substrates, gene rearrangements in cancer, and the potential clinical applications of kallikreins as diagnostic and therapeutic targets.
Dr. Diamandis’ research team is also working towards delineating the proteome of biological fluids and cancer cell lines to identify molecules that may represent novel cancer biomarkers for breast, ovarian, lung, prostate and other cancers. This research involves extensive use of tissue culture technologies, fractionation and purification with various chromatographic techniques and mass spectrometric analysis of fractionated proteins. The laboratory was the first to delineate the proteomes of amniotic and cervico-vaginal fluid. In the area of clinical proteomics, the research team is seeking to identify novel molecules or proteomic signatures that can be used for early detection of cancer, as well as prognosis and monitoring. Dr. Diamandis is a founding member and Principal Investigator of the Ontario Cancer Biomarker Network, a consortium which aims to discover, use and commercialize novel cancer biomarkers.